Alternative regimens for the prophylaxis of Mycobacterium avium complex in acquired immune deficiency syndrome (AIDS)

American Journal of Medicine

Volumn 102, Issue 5 C, 1997, Pages 28-31

  Currier, Judith S ^a   McCutchan, J Allen ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; INDINAVIR; RIFABUTIN; RITONAVIR; SAQUINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC PROPHYLAXIS; AREA UNDER THE CURVE; ARTICLE; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MYCOBACTERIOSIS; PRIORITY JOURNAL;

EID: 0030756058     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(97)00041-7     Document Type: Article

References (14)

1. Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med. 329:1993;828-833.
2. Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med. 335:1996;384-391.
3. Oldfield, EC, Dickinson G, Chung R, et al. Once weekly azithromycin for the prevention of Mycobacterium avium complex (MAC) infection in AIDS patients. (Abstr. 203.) 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996.
4. Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med. 335:1996;392-398.
5. + patients with CD4 counts ≤100 cells/ μL . (Abstr. 205.) 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, 1996.
6. Peeters TL. Erythromycin and other macrolides as prokinetic agents. Gastroenterology. 105:1993;1886-1899.
7. Meier A, Kirschner P, Springer B, et al. Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare. Antimicrob Agents Chemother. 38:1994;381-384.
8. Nash KA, Inderlied CB. Genetic basis of macrolide resistance in Mycobacterium avium isolated from patients with disseminated disease. Antimicrob Agents Chemother. 39:1995;2625-2630.
9. Crixivan® (Indinavir Sulfate) Package Insert. West Point, PA: Merck & Co., 1996.
10. Norvir® (Ritonavir Capsules) Package Insert. North Chicago, IL: Abbot Laboratories, 1996.
11. Young LS. Mycobacterium avium complex: current issues in prophylaxis and treatment. Formulary. 32:((suppl 1)):1997;S2-19.
12. Dunne MW, Havlir D, Dube M, et al. Prevention of Pneumocystis carinii pneumonia with azithromycin. (Abstr. Tu.B.410.) 11th International Conference on AIDS, Vancouver, British Columbia, 1996.
13. Crampton S, Craft JC, Notario G, et al. Prevention of Pneumocystis carinii pneumonia in AIDS patients by clarithromycin prophylaxis for Mycobacterium avium complex (MAC). (Abstr. 7.09.) 3rd International Conference on the Macrolides, Azalides and Streptogramins, Lisbon, Portugal, 1996.
14. Horsburgh CR Jr. Advances in the prevention and treatment of Mycobacterium avium disease. (Editorial.). N Engl J Med. 335:1996;428-430.